Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

Vaccine

Volumn 24, Issue 33-34, 2006, Pages 5937-5949

  Giannini, Sandra L ^a   Hanon, Emmanuel ^a   Moris, Philippe ^a   Van Mechelen, Marcelle ^a   Morel, Sandra ^a   Dessy, Francis ^a   Fourneau, Marc A ^a   Colau, Brigitte ^a   Suzich, Joann ^b   Losonksy, Genevieve ^b   Martin, Marie Thérèse ^a   Dubin, Gary ^a   Wettendorff, Martine A ^a  

^a GSK   (Belgium)

^b MEDIMMUNE   (United States)

Author keywords

Antibodies; AS04; B memory cells; Human papillomavirus; MPL; Vaccine

Indexed keywords

ALUMINUM SALT; EPITOPE; IMMUNOLOGICAL ADJUVANT; PHOSPHORYL LIPID A; TUMOR NECROSIS FACTOR ALPHA; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; B LYMPHOCYTE ACTIVATION; CELLULAR IMMUNITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; INNATE IMMUNITY; MEDICAL ASSESSMENT; MEMORY CELL; MONOCYTE; MOUSE; MULTICENTER STUDY; NONHUMAN; NORMAL HUMAN; PERSISTENT INFECTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SERODIAGNOSIS; UTERINE CERVIX CANCER; VERRUCA VULGARIS; VIRUS PARTICLE;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ALUMINUM COMPOUNDS; ANIMALS; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CAPSID PROTEINS; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; LIPID A; MACACA MULATTA; MICE; MICE, INBRED BALB C; MONOCYTES; NEUTRALIZATION TESTS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VIRAL PROTEINS; VIRAL VACCINES;

EID: 33746096523     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.06.005     Document Type: Article

References (73)

1. Franco E.L., and Harper D.M. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 23 17-18 (2005) 2388-2394
2. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 2 (2005) 74-108
3. Cogliano V., Baan R., Straif K., Grosse Y., Secretan B., and El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 6 4 (2005) 204
4. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., and zur Hausen H. Classification of papillomaviruses. Virology 324 1 (2004) 17-27
5. Schiffman M., Herrero R., DeSalle R., Hildesheim A., Wacholder S., Rodriguez A.C., et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337 1 (2005) 76-84
6. Muñoz N., Bosch F.X., de Sanjosé S., Herrero R., Castellsagué X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 6 (2003) 518-527
7. Walboomers J.M.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 1 (1999) 12-19
8. Bosch F.X., Lorincz A., Muñoz N., Meijer C.J.L.M., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55 4 (2002) 244-265
9. Muñoz N., Bosch F.X., Castellsagué X., Díaz M., de Sanjosé S., Hammouda D., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111 2 (2004) 278-285
10. Christensen N.D., Hopfl R., DiAngelo S.L., Cladel N.M., Patrick S.D., Welsh P.A., et al. Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J Gen Virol 75 Pt 9 (1994) 2271-2276
11. Hagensee M.E., Olson N.H., Baker T.S., and Galloway D.A. Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids. J Virol 68 7 (1994) 4503-4505
12. Rose R.C., Reichman R.C., and Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 75 Pt 8 (1994) 2075-2079
13. Kirnbauer R., Booy F., Cheng N., Lowy D.R., and Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89 24 (1992) 12180-12184
14. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 9447 (2004) 1757-1765
15. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 21 (2002) 1645-1651
16. Villa L.L., Costa R.L.R., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 5 (2005) 271-278
17. Breitburd F., Kirnbauer R., Hubbert N.L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., et al. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69 6 (1995) 3959-3963
18. Christensen N.D., Reed C.A., Cladel N.M., Han R., and Kreider J.W. Immunization with virus-like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 70 2 (1996) 960-965
19. Jansen K.U., Rosolowsky M., Schultz L.D., Markus H.Z., Cook J.C., Donnelly J.J., et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 13 16 (1995) 1509-1514
20. Kirnbauer R., Chandrachud L.M., O'Neil B.W., Wagner E.R., Grindlay G.J., Armstrong A., et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219 1 (1996) 37-44
21. Lin Y.L., Borenstein L.A., Selvakumar R., Ahmed R., and Wettstein F.O. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology 187 2 (1992) 612-619
22. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92 25 (1995) 11553-11557
23. Bernasconi N.L., Traggiai E., and Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298 5601 (2002) 2199-2202
24. Crotty S., Felgner P., Davies H., Glidewell J., Villarreal L., and Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 171 10 (2003) 4969-4973
25. Traggiai E., Puzone R., and Lanzavecchia A. Antigen dependent and independent mechanisms that sustain serum antibody levels. Vaccine 21 Suppl 2 (2003) S35-S37
26. Burdin N., Guy B., and Moingeon P. Immunological foundations to the quest for new vaccine adjuvants. BioDrugs 18 2 (2004) 79-93
27. Pashine A., Valiante N.M., and Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 11 4 Suppl (2005) S63-S68
28. Tomai M.A., and Johnson A.G. T cell and interferon-gamma involvement in the adjuvant action of a detoxified endotoxin. J Biol Response Mod 8 6 (1989) 625-643
29. Ulrich J.T., and Myers K.R. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol 6 (1995) 495-524
30. De Becker G., Moulin V., Pajak B., Bruck C., Francotte M., Thiriart C., et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int Immunol 12 6 (2000) 807-815
31. Ismaili J., Rennesson J., Aksoy E., Vekemans J., Vincart B., Amraoui Z., et al. Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol 168 2 (2002) 926-932
32. Martin M., Michalek S.M., and Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun 71 5 (2003) 2498-2507
33. Garçon N., Van Mechelen M., and Wettendorff M. Development and evaluation of AS04, a novel and improved immunological adjuvant system containing MPL and aluminium salt. In: Schijns V., and O'Hagan D. (Eds). Immunopotentiators in modern vaccines (2006), Elsevier Academic Press, London 161-177
34. Bernstein D.I., Aoki F.Y., Tyring S.K., Stanberry L.R., St Pierre C., Shafran S.D., et al. Safety and immunogenicity of glycoprotein d-adjuvant genital herpes vaccine. Clin Infect Dis 40 9 (2005) 1271-1281
35. Bourne N., Bravo F.J., Francotte M., Bernstein D.I., Myers M.G., Slaoui M., et al. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J Infect Dis 187 4 (2003) 542-549
36. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., et al. Glycoprotein-d-adjuvant vaccine to prevent genital herpes. N Engl J Med 347 21 (2002) 1652-1661
37. Boland G., Beran J., Lievens M., Sasadeusz J., Dentico P., Nothdurft H., et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 23 3 (2004) 316-320
38. Thoelen S., Van Damme P., Mathei C., Leroux-Roels G., Desombere I., Safary A., et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 16 7 (1998) 708-714
39. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 9518 (2006) 1247-1255
40. Matsuura M., Kiso M., and Hasegawa A. Activity of monosaccharide lipid A analogues in human monocytic cells as agonists or antagonists of bacterial lipopolysaccharide. Infect Immun 67 12 (1999) 6286-6292
41. Christensen N.D., Dillner J., Eklund C., Carter J.J., Wipf G.C., Reed C.A., et al. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223 1 (1996) 174-184
42. Wang Z., Christensen N., Schiller J.T., and Dillner J. A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol 78 Pt 9 (1997) 2209-2215
43. Pastrana D.V., Buck C.B., Pang Y.Y.S., Thompson C.D., Castle P.E., FitzGerald P.C., et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321 2 (2004) 205-216
44. Lenz P., Day P.M., Pang Y.Y.S., Frye S.A., Jensen P.N., Lowy D.R., et al. Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 166 9 (2001) 5346-5355
45. Lenz P., Thompson C.D., Day P.M., Bacot S.M., Lowy D.R., and Schiller J.T. Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells. Clin Immunol 106 3 (2003) 231-237
46. Ruiz W., McClements W.L., Jansen K.U., and Esser M.T. Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant. J Immune Based Ther Vaccines 3 1 (2005) 2
47. Yang R., Murillo F.M., Cui H., Blosser R., Uematsu S., Takeda K., et al. Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J Virol 78 20 (2004) 11152-11160
48. Yang R., Murillo F.M., Delannoy M.J., Blosser R.L., Yutzy W.H., Uematsu S., et al. B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol 174 12 (2005) 7912-7919
49. Rimaniol A.C., Gras G., Verdier F., Capel F., Grigoriev V.B., Porcheray F., et al. Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine 22 23-24 (2004) 3127-3135
50. Ulanova M., Tarkowski A., Hahn-Zoric M., and Hanson L.A. The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun 69 2 (2001) 1151-1159
51. Jordan M.B., Mills D.M., Kappler J., Marrack P., and Cambier J.C. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 304 5678 (2004) 1808-1810
52. Tiberio L., Fletcher L., Eldridge J.H., and Duncan D.D. Host factors impacting the innate response in humans to the candidate adjuvants RC529 and monophosphoryl lipid A. Vaccine 22 11-12 (2004) 1515-1523
53. Akira S., Takeda K., and Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2 8 (2001) 675-680
54. Medzhitov R., Preston-Hurlburt P., and Janeway Jr. C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388 6640 (1997) 394-397
55. Schnare M., Barton G.M., Holt A.C., Takeda K., Akira S., and Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2 10 (2001) 947-950
56. Baldridge J.R., McGowan P., Evans J.T., Cluff C., Mossman S., Johnson D., et al. Taking a Toll on human disease: toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 4 7 (2004) 1129-1138
57. Pasare C., and Medzhitov R. Control of B-cell responses by toll-like receptors. Nature 438 7066 (2005) 364-368
58. Hirschfeld M., Ma Y., Weis J.H., Vogel S.N., and Weis J.J. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol 165 2 (2000) 618-622
59. Tapping R.I., Akashi S., Miyake K., Godowski P.J., and Tobias P.S. Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J Immunol 165 10 (2000) 5780-5787
60. Marino M.W., Dunn A., Grail D., Inglese M., Noguchi Y., Richards E., et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 94 15 (1997) 8093-8098
61. Ritter U., Meissner A., Ott J., and Körner H. Analysis of the maturation process of dendritic cells deficient for TNF and lymphotoxin-α reveals an essential role for TNF. J Leukoc Biol 74 2 (2003) 216-222
62. Zhan Y., and Cheers C. Control of IL-12 and IFN-γ production in response to live or dead bacteria by TNF and other factors. J Immunol 161 3 (1998) 1447-1453
63. Mao C., Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Wiley D.J., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia. A randomized controlled trial. Obstet Gynecol 107 1 (2006) 18-27
64. Evans T.G., Bonnez W., Rose R.C., Koenig S., Demeter L., Suzich J.A., et al. A phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 183 10 (2001) 1485-1493
65. Pinto L.A., Edwards J., Castle P.E., Harro C.D., Lowy D.R., Schiller J.T., et al. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis 188 2 (2003) 327-338
66. Pinto L.A., Castle P.E., Roden R.B., Harro C.D., Lowy D.R., Schiller J.T., et al. HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Vaccine 23 27 (2005) 3555-3564
67. Dentico P., Crovari P., Lai P.L., Ponzio F., Safary A., Pellegrino A., et al. Anamnestic response to administration of purified non-adsorbed hepatitis B surface antigen in healthy responders to hepatitis B vaccine with long-term non-protective antibody titres. Vaccine 20 31-32 (2002) 3725-3730
68. Seto D., West D.J., and Ioli V.A. Persistence of antibody and immunologic memory in children immunized with hepatitis B vaccine at birth. Pediatr Infect Dis J 21 8 (2002) 793-795
69. West D.J., and Calandra G.B. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 14 11 (1996) 1019-1027
70. Hocini H., Barra A., Belec L., Iscaki S., Preud'homme J.L., Pillot J., et al. Systemic and secretory humoral immunity in the normal human vaginal tract. Scand J Immunol 42 2 (1995) 269-274
71. Kozlowski P.A., Cu-Uvin S., Neutra M.R., and Flanigan T.P. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 65 4 (1997) 1387-1394
72. Nardelli-Haefliger D., Wirthner D., Schiller J.T., Lowy D.R., Hildesheim A., Ponci F., et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 95 15 (2003) 1128-1137
73. Lowe R.S., Brown D.R., Bryan J.T., Cook J.C., George H.A., Hofmann K.J., et al. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J Infect Dis 176 5 (1997) 1141-1145